This inventor holds 2 USPTO granted patents. Top assignees: Brandeis University, Grenpharma LLC. Active years: 2009-2012.
Company Filing History:
Years Active: 2009-2012
Title: David Alan Kew: Innovator in Neurodegenerative Disease Treatment
Introduction
David Alan Kew is an accomplished inventor based in Worcester, MA (US). He has made significant contributions to the field of medical science, particularly in the treatment and prevention of neurodegenerative diseases. With a total of 2 patents, Kew's work focuses on innovative compositions that target diseases characterized by the presence of metal ions.
Latest Patents
Kew's latest patents revolve around compositions for treating and/or preventing diseases such as Alzheimer's disease. These inventions utilize organosilicon compounds that can be administered to mammals, including humans. The compositions may contain silanols, silandiols, silantriols, or cyclic organosilanes, which can form under physiological conditions. Notably, these organosilicon compounds can be bound to moieties that facilitate transport across the blood-brain barrier. This innovative approach may also involve the sequestration of harmful metal ions like aluminum, copper, and iron, enhancing the therapeutic potential of the compositions.
Career Highlights
Throughout his career, Kew has worked with notable organizations, including Grenpharma LLC and Brandeis University. His experience in these institutions has allowed him to collaborate with other experts in the field, further advancing his research and innovations.
Collaborations
Some of Kew's coworkers include Orrie Friedman and Ivan Correia. Their collaborative efforts have contributed to the development of groundbreaking solutions in the treatment of neurodegenerative diseases.
Conclusion
David Alan Kew's innovative work in the field of neurodegenerative disease treatment showcases his dedication to improving human health. His patents reflect a commitment to addressing complex medical challenges through scientific innovation.